News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Adaptimmune Therapeutics plc Prices Public Offering of American Deposi

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares22/03/2017Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares (“ADSs”) at a price to the public of $4.20 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an addition


2. U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initi

U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis22/03/2017Groundbreaking UK/US Initiative Will Deliver First Data Within a YearRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resourc


3. Adaptimmune Therapeutics plc Announces Closing of $42 Million Register

Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering19/04/2017Philadelphia, USA and Oxford, UK: Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately


4. Adaptimmune Therapeutics plc Announces Registered Direct Offering of A

Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares05/04/2017Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its American Depositary Shares (“ADSs”) in a registered direct offering. The t


5. Endo International plc Announces Proposed Private Offering of Senior S

Endo International plc Announces Proposed Private Offering of Senior Secured Notes10/04/2017Endo International plc (NASDAQ: ENDP) ("Endo") today announced that Endo Designated Activity Company, Endo Finance LLC and Endo Finco Inc. (collectively, the "Issuers"), its wholly-owned subsidiaries, intend to offer senior secured notes, subject to market and customary conditions. The notes will be senior obligations of the Issuers and will be guaranteed by Endo and certain of Endo's subsidiaries and wil



Page 23 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019